thalidomide has been researched along with Acquired Hyperostosis Syndrome in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Acquired Hyperostosis Syndrome: Syndrome consisting of SYNOVITIS; ACNE CONGLOBATA; PALMOPLANTAR PUSTULOSIS; HYPEROSTOSIS; and OSTEITIS. The most common site of the disease is the upper anterior chest wall, characterized by predominantly osteosclerotic lesions, hyperostosis, and arthritis of the adjacent joints. The association of sterile inflammatory bone lesions and neutrophilic skin eruptions is indicative of this syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pathogenesis of SAPHO syndrome remains unclear, but evidence suggests it may be an autoinflammatory disease triggered upon exposure to infectious agents in genetically predisposed individuals." | 5.48 | Successful treatment of SAPHO syndrome with apremilast. ( Adamo, S; Cozzio, A; French, LE; Kolios, AGA; Krebs, A; Nilsson, J; Steiner, U, 2018) |
| "A FREQUENT AFFECTION: Ankylosing spondylitis is a chronic inflammatory rheumatism usually affecting young adults and characterized by an inflammatory enthesiopathy progressing towards ossification and ankylosis." | 2.42 | [Ankylosing spondylitis]. ( El Maghraoui, A, 2004) |
| "The pathogenesis of SAPHO syndrome remains unclear, but evidence suggests it may be an autoinflammatory disease triggered upon exposure to infectious agents in genetically predisposed individuals." | 1.48 | Successful treatment of SAPHO syndrome with apremilast. ( Adamo, S; Cozzio, A; French, LE; Kolios, AGA; Krebs, A; Nilsson, J; Steiner, U, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamo, S | 1 |
| Nilsson, J | 1 |
| Krebs, A | 1 |
| Steiner, U | 1 |
| Cozzio, A | 1 |
| French, LE | 1 |
| Kolios, AGA | 1 |
| Firinu, D | 1 |
| El Maghraoui, A | 1 |
1 review available for thalidomide and Acquired Hyperostosis Syndrome
| Article | Year |
|---|---|
[Ankylosing spondylitis].
Topics: Acquired Hyperostosis Syndrome; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 2004 |
2 other studies available for thalidomide and Acquired Hyperostosis Syndrome
| Article | Year |
|---|---|
Successful treatment of SAPHO syndrome with apremilast.
Topics: Acquired Hyperostosis Syndrome; Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Resistance; Fem | 2018 |
A promising new treatment for SAPHO syndrome that deserves further studies.
Topics: Acquired Hyperostosis Syndrome; Humans; Thalidomide | 2018 |